Brought to you by 
Exscientia raises $26mm in Series B round
18 Jan 2019
Executive Summary
AI drug discovery company Exscientia Ltd. raised $26mm in its Series B financing round from new investors Celgene and specialist health care investor GT Healthcare Capital Partners along with returning backer Evotec. The company plans to use the proceeds to scale its pipeline and advance selected programs toward the clinic. Exscientia expects its first programs driven by AI to be IND-ready within the next year.
Deal Industry
- Digital Health
- Pharmaceuticals
- Services
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Exscientia raises $26mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice